Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director with effect from 25 June.
Tooman most recently served as president, chief executive and board director of Silence Therapeutics, the Nasdaq-listed siRNA company.
He brings more than 30 years of pharmaceutical and biotechnology leadership experience spanning clinical, operational, financial and capital markets roles.
The company said Tooman had directly participated in raising nearly $9 billion in capital across his executive and board roles.
At Silence Therapeutics, he helped transform the business from an early-stage UK research enterprise trading mainly on AIM into a well-financed Nasdaq-listed global developer.
Coiled said his career included a string of strategic transactions.
As chief executive of Aratana Therapeutics (NASDAQ:PETX), he negotiated its $250 million merger with Elanco, while at ILEX Oncology he led a $1.1 billion acquisition by Genzyme (NASDAQ:GENZ).
He also served on the supervisory board of CureVac until its acquisition by BioNTech in 2025.
Coiled said his oncology background aligned with its precision medicine focus and lead candidate, AO-252.
Chairman Sotirios Stergiopoulos said Tooman's public company track record and ability to finance and scale clinical-stage companies would be valuable as the company advanced AO-252 through the clinic and broadened its investor base.
